Traditional protein therapeutic treatments require large doses of short acting medicine on top of the high costs of production and cold chain logistics. MYO Technology removes these hurdles with long-lasting, less-frequent, more streamlined treatment regimens without the logistical hurdles of cold chain management and long, costly, manufacturing processes.
https://www.renbio.com/news_and_events/renbio-announces-new-awards-to-support-continued-development-of-its-novel-dna-based-myo-technologytm-platform-for-antiviral-applications/
The flexibility
to go further
MYO Technology is superior
MYO Technology is a platform
MYO Technology is a true platform technology with the flexibility to go beyond traditional treatment paradigms. By varying the DNA blueprints being delivered, MYO Technology can support virtually any encoded protein product.
Clinical Applications
Blood disorders
Long-lasting delivery of therapeutic proteins can improve treatment of chronic blood disorders.
Inflammatory diseases
Monoclonal antibodies are a critical class of drugs for treatment of inflammatory diseases.
Viral infections
Viral infections can be prevented by the prophylactic use of antiviral antibodies, and their delivery with MYO Technology would provide lasting protection.